ATEN stock analysis: A10 Networks just put up the kind of quarter that gets small-cap investors interested fast. First-quarter 2026 revenue climbed to $75.0 million, up 13.4% year over year, product revenue jumped 22.3%, and management leaned hard into the idea that AI infrastructure is becoming a traffic-management and security problem before it becomes just …
Rigel Pharmaceuticals looks cheap for a reason, but it may still be too cheap. At roughly $32.08 per share and a $592.6 million market cap on June 12, 2026, the stock screens like a mistake: a reported trailing P/E of about 1.66, positive net income, and a commercial biotech business that just posted another profitable …
EverQuote just printed another strong quarter, and the business is cleaner than most small-cap internet names. Q1 2026 revenue grew 15% year over year to $190.9 million, adjusted EBITDA rose 30% to a record $29.3 million, and the company ended the quarter with $178.5 million in cash and no debt. For a stock with a …
# HYLN Stock Analysis: Real Catalyst, Real Execution Risk Hyliion finally has something better than a concept slide. Q1 2026 revenue came in at $2.8 million, up from $0.5 million a year ago, and the company just cleared non-recurring UL certification testing across the battery system, linear electric motor, and full KARNO Power Module. That …
If you want the short version, a safe withdrawal rate in 2026 is probably closer to 3.5% to 3.9% for most early retirees, not the lazy internet version of 4% that gets repeated like gospel. That does not mean the 4% rule is fake. It means your retirement timeline, healthcare costs, and willingness to cut …
If you want the short version, the best dividend stocks for 2026 are Realty Income (O), AbbVie (ABBV), and Chevron (CVX). They are not the highest-yield names on the screen, but that is the point. I would rather own a 3% to 6% yielder with real revenue, real balance-sheet support, and a visible 2026 catalyst …
Yext (NYSE: YEXT) looks dull until you get past the stock chart. The business did $446.6 million in fiscal 2026 revenue, produced $107.3 million in adjusted EBITDA, stayed profitable, and now has an AI-search product management thinks can matter. That is the bull case. The bear case is easier: this is still a slow-growth software …
ARDX Stock Analysis: Growth Is Real, So Is the Spend Ardelyx just posted the kind of quarter biotech investors usually beg for: real product revenue, real growth, and enough cash to avoid the usual panic about the next dilutive raise. The catch is that ARDX is no longer a cheap story. At roughly a $1.7 …
Agenus is a real biotech catalyst trade, not a hidden value stock. At roughly a $144 million market cap, with Phase 2 melanoma data due at ASCO on May 31 and a first-quarter corporate update scheduled for May 11, the setup is obvious: if the botensilimab story keeps getting cleaner, the stock can move fast. …
PROK stock is one of those setups where the upside story is obvious and the holding-period pain is obvious too. ProKidney has a sub-$300 million market cap, roughly $271.7 million in cash from its last reported quarter, a Phase 3 kidney-disease program with FDA alignment on an accelerated path, and a stock that still trades …